Fc Receptor (FcR) and Antibody Effector Function in HIV Vaccine Discovery (R01) | Apply Online

Frequently Asked Questions (FAQs)

What is the title and funding opportunity number for this grant?

The opportunity is titled "Fc Receptor (FcR) and Antibody Effector Function in HIV Vaccine Discovery (R01)" and the Funding Opportunity Number is PA-14-218.

What type of grant mechanism is this?

This is an NIH R01 research grant mechanism. It is described as an NIH discretionary research grant program supporting investigator-driven research projects.

What is the scientific purpose of this funding opportunity?

The program is designed to push HIV vaccine research beyond measuring antibody quantity alone and toward understanding antibody function in the body. The focus is on how vaccine-elicited antibodies may help prevent HIV acquisition not only by neutralizing virus directly, but also by recruiting immune cells through Fc receptor (FcR) interactions mediated by the antibody Fc region.

What is the central idea behind studying Fc receptors (FcRs) in HIV vaccine discovery?

The central idea is that antibodies induced by vaccination may contribute to protection via Fc-dependent pathways, where the Fc portion of antibodies engages Fc receptors on immune cells and triggers effector functions that may reduce infection risk or help control virus during the earliest stages of exposure.

What kinds of antibody functions are emphasized (beyond neutralization)?

The opportunity highlights Fc-mediated antibody effector functions such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement activation, and other Fc-mediated activities that depend on Fc-FcR binding.

Which immune cells are specifically mentioned as relevant to Fc-mediated functions?

The FOA mentions immune cells that express Fc receptors and can be recruited by antibodies, including NK cells, monocytes, macrophages, neutrophils, and dendritic cells.

What kinds of research questions does the FOA encourage?

The FOA encourages mechanistic research to clarify how FcR-mediated antibody effector functions contribute to protection and how those functions can be intentionally elicited and optimized by vaccination. It also encourages disentangling which FcR pathways matter most, under what conditions they operate, and how antibody features influence FcR engagement and outcomes relevant to protection.

What antibody features are called out as important for FcR engagement and function?

The FOA specifically calls out antibody subclass, isotype, glycosylation, epitope specificity, and binding strength as features that can influence FcR engagement and the downstream effector functions.

What does "mechanistic research" mean in the context of this FOA?

In this context, mechanistic research refers to studies aimed at defining how Fc-dependent pathways work (the FcR mechanisms and immune effector pathways involved) and how vaccine-elicited antibodies can block viral acquisition through those Fc-dependent mechanisms.

Does this FOA support work aimed at causality, not just correlation?

Yes. The description includes support for animal or other preclinical investigations that can test causality and protective effects, in addition to laboratory and clinical sample analyses.

What is meant by "benchmarking" in this FOA?

Benchmarking refers to building functional profiles of vaccines known to protect against viral infections and using those profiles as reference points for HIV vaccine development. The intent is to compare functional antibody signatures across vaccines and settings to help guide HIV vaccine candidate decisions.

Why does the FOA emphasize benchmarking against vaccines known to protect?

The FOA emphasizes benchmarking so HIV vaccine candidates are not evaluated in isolation. By comparing to functional profiles seen in successful vaccines or protective settings, researchers can look for patterns of protective Fc-mediated functions and generate clearer go/no-go signals and more informative immune correlates.

What kinds of comparisons does the FOA anticipate for benchmarking work?

The FOA describes comparative work across vaccine platforms, antigens, adjuvants, and immunization regimens, with emphasis on parameters that plausibly drive protection rather than simply correlate with exposure.

What kinds of studies and materials does the FOA support (basic, preclinical, clinical)?

The FOA supports basic and preclinical research as well as analysis of clinical samples. This includes laboratory studies to define FcR mechanisms and effector pathways, preclinical investigations (including animal studies) to test protective effects, and use of specimens from clinical trials to evaluate Fc-dependent functions in humans.

What does the FOA mean by evaluating "parameters critical for the elicitation of protective FcR antibody effector function"?

As described, this means both (1) characterizing functional output (what immune activities the antibodies trigger) and (2) identifying upstream determinants, including vaccine design choices and antibody molecular properties, that lead to those functional outputs.

Are projects expected to be collaborative?

Yes. The FOA describes the research as investigator-driven and collaborative, reflecting interest in coordinated efforts and cross-disciplinary teams that may combine immunology, virology, vaccinology, assay development, and clinical sample analysis.

What program area or category is this opportunity associated with?

The opportunity is categorized under Health and is associated with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).

What was the posting date and when did the opportunity close?

The announcement was posted on May 12, 2014. The original and current closing date was January 7, 2017, and the archive date was February 7, 2017.

Is this funding opportunity still active?

No. The closing and archive dates indicate the FOA is no longer active, though it remains a useful reference for the types of studies NIH has prioritized in this area.

Who was eligible to apply?

Eligibility was broad and included many organization types, including public and private institutions of higher education; nonprofits with and without 501(c)(3) status; small businesses and other for-profit organizations; state and local governments (including counties, cities, townships, and special districts); independent school districts; public housing authorities; Native American tribal governments and tribal organizations; and additional categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, AANAPISIs, faith-based and community-based organizations, U.S. territories and possessions, non-U.S. entities (foreign organizations), regional organizations, and eligible federal agencies.

Are foreign (non-U.S.) organizations eligible?

Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations), as well as regional organizations.

Was cost sharing or matching required?

No. The FOA specified no cost sharing or matching requirement.

Where can the full FOA be found?

The FOA was hosted by NIH at http://grants.nih.gov/grants/guide/pa-files/PA-14-218.html.

Who is listed as a contact for access or linking issues?

NIH provided contacts through the NIH Office of Extramural Research (OER) webmaster addresses for access or linking issues.